(RTTNews) – Palatin Technologies, Inc. (PTNT), a biopharmaceutical company advancing melanocortin-based therapies, shared new preclinical findings at the 2025 ARVO Annual Meeting.
The results highlight the therapeutic potential of melanocortin agonists PL9654 and PL9655 in treating diabetic retinopathy (DR). These compounds demonstrated strong anti-inflammatory effects, stabilization of the blood-retinal barrier, reduction in VEGF signaling, and protection of retinal ganglion cells—factors central to DR progression.
Both PL9654 and PL9655 showed efficacy across several administration routes, including topical, and in various disease models. The presented data underscore their ability to preserve vision, reduce inflammation, and suppress abnormal blood vessel growth.
CEO Carl Spana emphasized the multi-pathway action of the treatments, noting their ability to modulate immune responses, curb angiogenesis, and maintain neural health, particularly through non-invasive topical delivery. Dr. Paul Kayne, VP of Biological Sciences, presented the research under the title: „Activating the melanocortin system resolves inflammation, reduces VEGF signaling in
Dieser Beitrag wurde original veröffentlicht auf: link zum Beitrag
